We are live on ! Find out more
CNSP icon

CNS Pharmaceuticals
CNSP

7 hedge funds and large institutions have $75.3K invested in CNS Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 1 increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

500% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 1

250% more funds holding

Funds holding: 2 → 7 (+5)

0.03% less ownership

Funds ownership: 0.03% → 0% (-0.03%)

67% less capital invested

Capital invested by funds: $228K → $75.3K (-$153K)

Holders
7
Holders Change
+5
Holders Change %
+250%
% of All Funds
0.1%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
1
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Geode Capital Management
Geode Capital Management
Massachusetts
+$97.2K
2
UBS Group
UBS Group
Switzerland
+$85.8K
3
VF
Virtu Financial
New York
+$58.8K
4
Goldman Sachs
Goldman Sachs
New York
+$13.5K
5
Jane Street
Jane Street
New York
+$11.2K

Top Sellers

Rank Fund Capital Flow
1
AFM
Anson Funds Management
Texas
-$223K
2
Morgan Stanley
Morgan Stanley
New York
-$3
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$2

CNSP Hedge Fund Activity: Q3 2024 in Review

7 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in CNS Pharmaceuticals (CNSP) for Q3 2024, worth a combined $75.3K — down 67% from $228K a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new CNSP positions and 1 closed out — a net gain of 5 holders — while 1 added to existing stakes and 0 trimmed.

The largest buyer was Geode Capital Management, opening a new position worth an estimated $97.2K. The largest seller was Anson Funds Management, exiting entirely with an estimated $223K sold.

  • 7 institutional investors held CNS Pharmaceuticals (CNSP) as of Q3 2024, up from 2 in Q2 2024.
  • Funds reported $75.3K of CNS Pharmaceuticals stock for Q3 2024, down 67% quarter-over-quarter.
  • 6 funds opened new CNS Pharmaceuticals positions in Q3 2024 and 1 closed out, a net change of +5 holders.
  • The largest CNS Pharmaceuticals buyer in Q3 2024 was Geode Capital Management, an estimated $97.2K added.
  • The largest CNS Pharmaceuticals seller in Q3 2024 was Anson Funds Management, an estimated $223K sold.

Based on aggregated 13F filings for Q3 2024.